Isotretinoin for Cutaneous Sarcoidosis: A Potential Therapy

Authors

  • Caroline Oktarina Universitas Indonesia
  • Yudo Irawan
  • Sandra Widaty

Keywords:

sarcoidosis, isotretinoin, management

Abstract

Sarcoidosis is a chronic noncaseating granulomatous disorder with clinical manifestations involving various organs, including skin. The incidence of sarcoidosis reached 35.5 – 64 cases per 100,000 people in the United States while Dr. Cipto Mangunkusumo National Central General Hospital, Jakarta reported the incidence of cutaneous sarcoidosis of 0.07% in 2015-2019. Numerous treatment modalities have been developed for the treatment of sarcoidosis and steroid becomes the first-line treatment for sarcoidosis. However, cases of sarcoidosis recalcitrant towards steroid are often reported, leading to consideration of other medications with possible efficacy on sarcoidosis, one of which is isotretinoin. Isotretinoin plays a role in sarcoidosis through its effect on inhibiting Tumor Necrosis Factor (TNF) and enhancing the production of prostaglandin E2 (PGE2). Based on several studies reported, level of evidence (LoE) of isotretinoin for the management of cutaneous sarcoidosis is level IV. Therefore, albeit being quite potential for the management of cutaneous sarcoidosis, further studies are necessary to prove the effectiveness of isotretinoin.

References

Wanat KA, Rosenbach M. Cutaneous sarcoidosis. Clin Chest Med. 2015;36:685-702.

El-Khalawany M, Mosbeh A, Aboeldahab S, Ali S. Cutaneous sarcoidosis: A new subset in the spectrum of paraneoplastic dermatoses. Clin Exp Dermatol. 2018;43:683-91.

Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: A comprehensive review and update for the dermatologist: Part I. Cutaneous disease. J Am Acad Dermatol. 2012;66:699 e1-18; quiz 717-8.

Noe MH, Rosenbach M. Cutaneous sarcoidosis. Curr Opin Pulm Med. 2017;23:482-6.

El Jammal T, Jamilloux Y, Gerfaud-Valentin M, Valeyre D, Seve P. Refractory sarcoidosis: A review. Ther Clin Risk Manag. 2020;16:323-45.

On SC, Zeichner J. Isotretinoin updates. Dermatol Ther. 2013;26:377-89.

Georgiou S, Monastirli A, Pasmatzi E, Tsambaos D. Cutaneous sarcoidosis: Complete remission after oral isotretinoin therapy. Acta Derm Venereol. 1998;78:457-9.

Arkema EV, Cozier YC. Epidemiology of sarcoidosis: Current findings and future directions. Ther Adv Chronic Dis. 2018;9:227-40.

Inaoka PT, Shono M, Kamada M, Espinoza JL. Host-microbe interactions in the pathogenesis and clinical course of sarcoidosis. J Biomed Sci. 2019;26:45.

Bordignon M, Rottoli P, Agostini C, Alaibac M. Adaptive immune responses in primary cutaneous sarcoidosis. Clin Dev Immunol. 2011;2011:235142.

Ungprasert P, Ryu JH, Matteson EL. Clinical manifestations, diagnosis, and treatment of sarcoidosis. Mayo Clin Proc Innov Qual Outcomes. 2019;3:358-75.

Haimovic A, Sanchez M, Judson MA, Prystowsky S. Sarcoidosis: A comprehensive review and update for the dermatologist: Part II. Extracutaneous disease. J Am Acad Dermatol. 2012;66:719 e1-10; quiz 29-30.

Marchell R. Sarcoidosis. In: Kang S, Amagai M, Bruckner AL, Enk AH, Margolis DJ, McMichael AJ, et al., editors. Fitzpatrick's dermatology. 9th ed. USA: McGraw-Hill Education; 2019. p. 572-84.

Lowenstein EB, Lowenstein EJ. Isotretinoin systemic therapy and the shadow cast upon dermatology's downtrodden hero. Clinics in Dermatology. 2011;29:652-61.

Waldinger TP, Ellis CN, Quint K, Voorhees JJ. Treatment of cutaneous sarcoidosis with isotretinoin. Arch Dermatol. 1983;119:1003-5.

Spiteri MA, Taylor SJ. Retinoids in the treatment of cutaneous sarcoidosis. Arch Dermatol. 1985;121:1486.

Vaillant L, le Marchand D, Bertrand S, Grangeponte MC, Lorette G. [annular cutaneous sarcoidosis of the forehead: Treatment with isotretinoin]. Ann Dermatol Venereol. 1986;113:1089-92.

Mosam A, Morar N. Recalcitrant cutaneous sarcoidosis: An evidence-based sequential approach. J Dermatolog Treat. 2004;15:353-9.

Chong WS, Tan HH, Tan SH. Cutaneous sarcoidosis in asians: A report of 25 patients from Singapore. Clin Exp Dermatol. 2005;30:120-4.

Choi KH, Kim SY, Kim GM. A case of cutaneous sarcoidosis treated with isotretinoin. Korean J Dermatol. 2009;47:629-31.

Hossein M, Nessa A, Maryam G, Vahideh L. A review of three systemic retinoids in dermatology: Acitretin, isotretinoin and bexarotene. Iran J Dermatol. 2013;16:144-58.

Wolter NJ, Kunkel SL, Lynch JP, 3rd, Ward PA. Production of cyclooxygenase products by alveolar macrophages in pulmonary sarcoidosis. Chest. 1983;83:79s-81s.

Kasama T, Kobayashi K, Yamagata N, Iwabuchi H, Matsuda T, Nakatani K, et al. Augmentation of pulmonary foreign body granulomatous inflammation in mice by lipopolysaccharide: Involvement of macrophage activation and tumor necrosis factor-alpha. Int Arch Allergy Immunol. 1992;97:130-8.

Nakayama T, Hashimoto S, Amemiya E, Horie T. Elevation of plasma-soluble tumour necrosis factor receptors (TNF-r) in sarcoidosis. Clin Exp Immunol. 1996;104:318-24.

Totpal K, Chaturvedi MM, LaPushin R, Aggarwal BB. Retinoids downregulate both p60 and p80 forms of tumor necrosis factor receptors in human histiocytic lymphoma u-937 cells. Blood. 1995;85:3547-55.

Mehta K, McQueen T, Tucker S, Pandita R, Aggarwal BB. Inhibition by all-trans-retinoic acid of tumor necrosis factor and nitric oxide production by peritoneal macrophages. J Leukoc Biol. 1994;55:336-42.

Hong K, Zhang Y, Guo Y, Xie J, Wang J, He X, et al. All-trans retinoic acid attenuates experimental colitis through inhibition of nf-kappab signaling. Immunol Lett. 2014;162:34-40.

Levine L, Ohuchi K. Retinoids as well as tumour promoters enhance deacylation of cellular lipids and prostaglandin production in mdck cells. Nature. 1978;276:274-5.

Hill MR, Papafili A, Booth H, Lawson P, Hubner M, Beynon H, et al. Functional prostaglandin-endoperoxide synthase 2 polymorphism predicts poor outcome in sarcoidosis. Am J Respir Crit Care Med. 2006;174:915-22.

Mamidi S, Hofer TP, Hoffmann R, Ziegler-Heitbrock L, Frankenberger M. All-trans retinoic acid up-regulates prostaglandin-e synthase expression in human macrophages. Immunobiology. 2012;217:593-600.

Downloads

Published

2023-08-07

How to Cite

1.
Oktarina C, Irawan Y, Widaty S. Isotretinoin for Cutaneous Sarcoidosis: A Potential Therapy. J Pak Assoc Dermatol [Internet]. 2023Aug.7 [cited 2025Feb.7];33(3):1096-105. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/2294

Issue

Section

Review Articles

Most read articles by the same author(s)